Business & Finance
C-Rad reduces loss in Q3 2017
30 October 2017 -

C-Rad AB (STO:CRADB), a developer of solutions for use in advanced radiation therapy, on Friday reported a loss per share of SEK0.05, or an operating loss of SEK1.4m, for the third quarter of 2017, from July 2017 to September 2017.

This was an improvement over loss per share of SEK0.29, or operating loss of SEK7.9m, in Q3 2016.

Revenues for the quarter were SEK33.2m, up by 48% as compared with SEK22.5m in Q3 2016.

Order intake for the quarter was SEK55.5m, up by 97% as compared with SEK28.2m in Q3 2016.

Also, the order back log at the end of the quarter doubled over last year's SEK68m and amounted to about SEK140m, out of which SEK100m related to Products and SEK40m related to Life Cycle Business (Service and support).

C-RAD offers products and solutions for patient positioning, tumour localisation and radiation treatment systems. All product development is conducted in the three fully owned subsidiaries of C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB.